Antibody therapeutics revolutionised how diseases like cancer are treated in the developed world, but their high manufacturing cost and cumbersome distribution and administration leave them out of reach for most. In this guest article, Lumen Bioscience’s CEO, Brian Finrow, and EVP of Production & Development, Craig Behnke, discuss how new technologies are making mass-market antibody drugs feasible for ultra-prevalent diseases like COVID-19 for the first time.
Magic bullets for all: democratising biologics by rethinking antibody development, manufacturing and delivery
Recent Post
Cognition Live Article on RePreve Trial
LMN-201 Achieves 100% Initial C. difficile Clinical Cure in Preliminary Cohort of RePreve Trial
Preventive antimicrobials: A promising solution to antibiotic resistance
Preventive Biologics May Aid the Antibiotic Resistance Crisis
Q&A: Biologic drugs are reinvented to treat infectious diseases